Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Idrugs : the Investigational Drugs Journal|March 4, 2008
Hepatocellular carcinoma (HCC): current and evolving therapiesRobert G Gish, Ari Baron
Cancers|September 10, 2021
Niraparib Suppresses Cholangiocarcinoma Tumor Growth by Inducing Oxidative and Replication StressVladimir Bezrookove, John M Patino, Mehdi Nosrati, et al.
Liver Cancer|November 1, 2021
Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular CarcinomaArndt Vogel, Catherine Frenette, Max Sung, et al.
The New England Journal of Medicine|June 4, 2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerHerbert Hurwitz, Louis Fehrenbacher, William Novotny, et al.
Oncology|May 3, 2018
A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular CarcinomaMelanie B Thomas, Elizabeth Garrett-Mayer, Munazza Anis, et al.
JAMA Oncology|December 8, 2022
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without IpilimumabJennifer L McQuade, Hans Hammers, Helena Furberg, et al.
The Lancet. Oncology|January 30, 2017
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialPadmanee Sharma, Margitta Retz, Arlene Siefker-Radtke, et al.
Cancer Chemotherapy and Pharmacology|April 11, 2014
An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumorsPierre Maison-Blanche, Shaker Dakhil, Ari Baron, et al.
Lancet (London, England)|February 14, 2018
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialMasatoshi Kudo, Richard S Finn, Shukui Qin, et al.
Pageof 1